BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29136692)

  • 1. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].
    Liu HQ; Zou BQ; Wang SY
    Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
    Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N
    Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908
    [No Abstract]   [Full Text] [Related]  

  • 3. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.
    Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K
    Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the immunoescape in colorectal cancer liver metastasis.
    Takasu C; Yamashita S; Morine Y; Yoshikawa K; Tokunaga T; Nishi M; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2021; 16(11):e0259940. PubMed ID: 34797860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
    Mandarano M; Bellezza G; Belladonna ML; Van den Eynde BJ; Chiari R; Vannucci J; Mondanelli G; Ludovini V; Ferri I; Bianconi F; Del Sordo R; Cagini L; Albini E; Metro G; Puma F; Sidoni A
    Virchows Arch; 2019 Feb; 474(2):159-168. PubMed ID: 30448912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
    Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
    Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
    Hacking S; Vitkovski T; Jain S; Jin C; Chavarria H; Wu D; Nasim M
    Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):201-208. PubMed ID: 32842025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
    Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT
    Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
    Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Nakao T; Kashihara H; Wada Y; Yoshimoto T; Okikawa S; Yamashita S; Shimada M
    BMC Cancer; 2022 Dec; 22(1):1263. PubMed ID: 36471264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.
    Kim JW; Nam KH; Ahn SH; Park DJ; Kim HH; Kim SH; Chang H; Lee JO; Kim YJ; Lee HS; Kim JH; Bang SM; Lee JS; Lee KW
    Gastric Cancer; 2016 Jan; 19(1):42-52. PubMed ID: 25424150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
    Hacking S; Chavarria H; Jin C; Perry A; Nasim M
    Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
    Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
    J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
    Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
    Front Immunol; 2020; 11():120. PubMed ID: 32117271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
    Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
    Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
    Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
    Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.